15 Jun 2026·Department of Health and Social Care·Answered
AskedWith the withdrawal of liquid hydrocortisone what steps is his department is taking to source a suitable alternative liquid hydrocortisone product for use in the UK.
ReplyThe Department is aware of the discontinuation of hydrocortisone sodium phosphate 100 milligram/1 millilitre solution for injection, and we continue to work with industry to find a longer-term solution.Hydrocortisone sodium succinate 100 milligram powder ...
15 Jun 2026·Department of Health and Social Care·Answered
AskedIf he will work with Pfizer to accelerate the UK licensing of the ‘ACT-O-VIAL’ dual-compartment hydrocortisone product containing pre-measured doses of powder and water for immediate mixing.
ReplyThe Department is aware of the discontinuation of hydrocortisone sodium phosphate 100 milligram/1 millilitre solution for injection, and we continue to work with industry to find a longer-term solution.Hydrocortisone sodium succinate 100 milligram powder ...
15 Jun 2026·Department of Health and Social Care·Answered
AskedWhat steps his Department is taking, in collaboration with the Office for Life Sciences, to support and fast-track the development of safer hydrocortisone delivery methods; and what assessment he h
ReplyThe Department is aware of the discontinuation of hydrocortisone sodium phosphate 100 milligram/1 millilitre solution for injection, and we continue to work with industry to find a longer-term solution.Hydrocortisone sodium succinate 100 milligram powder ...
10 Jun 2026·Department of Health and Social Care·Answered
AskedIf he will ringfence protected funding for children's brain cancer research separate from wider cancer budgets.
ReplyGovernment responsibility for delivering cancer research is shared between the Department for Health and Social Care with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Tech...
9 Jun 2026·Department of Health and Social Care·Answered
AskedWhat plans his Department has for a national strategy for the prevention of Young Sudden Cardiac Death.
ReplyThe Government recognises the devastating impact of sudden cardiac death on young people, families, and communities.To reduce the risks of sudden cardiac death, NHS England has a published a national service specification for Inherited Cardiac Conditions ...
8 Jun 2026·Department of Health and Social Care·Answered
AskedWhether his Department plans to review the current criteria for medical exemption certificates for prescription charges to include Arrhythmogenic Cardiomyopathy.
ReplyThere are no current plans to review the list of prescription charge exemptions or the list of medical conditions that entitle someone to apply for a medical exemption certificate. The Government has not specifically assessed the impact on patient health ...
8 Jun 2026·Department of Health and Social Care·Answered
AskedWhat assessment has been made of the potential impact on patient health outcomes if individuals with Arrhythmogenic Cardiomyopathy are unable to afford their prescribed medication.
ReplyThere are no current plans to review the list of prescription charge exemptions or the list of medical conditions that entitle someone to apply for a medical exemption certificate. The Government has not specifically assessed the impact on patient health ...
13 May 2026·Department of Health and Social Care·Answered
AskedWhether any (a) vaccines and (b) alternative preventative treatments for recurrent urinary tract infections are (i) currently under review by UK regulatory bodies and (ii) expected to enter the UK
ReplyThe Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department and regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring medicines meet ap...
13 May 2026·Department of Health and Social Care·Answered
AskedWhether he plans to take steps to (a) prioritise and (b) increase the speed of access to (i) vaccines and (ii) other preventative treatments for recurrent urinary tract infections, once approved.
ReplyThe National Institute for Health and Care Excellence (NICE) evaluates new licensed medicines, to determine whether they represent a clinically effective and cost-effective use of National Health Service resources. NICE aims to publish guidance on new med...
13 May 2026·Department of Health and Social Care·Answered
AskedWhat steps he is taking to ensure that every Integrated Care Board in England has a dedicated care pathway in place for people living with young onset dementia.
ReplyNHS England is committed to delivering high quality care and support for every person with dementia at every age, and central to this is the provision of personalised care.The Well Pathway for Dementia highlights that services need to be integrated, commi...
28 Apr 2026·Department of Health and Social Care·Pending
AskedWhat assessment he has made of the potential impact of increased use of online consultation systems on total demand for GP services; and whether additional funding has been provided to practices to meet any increase in workload arising from that demand.
28 Apr 2026·Department of Health and Social Care·Pending
AskedWhat assessment he has made of the financial and workforce impact of the requirement to deliver same-day responses to all clinically urgent requests under the 2026/27 GP contract on GP practices.
28 Apr 2026·Department of Health and Social Care·Pending
AskedWhether he has made an assessment of the adequacy of the level of funding in the 2026/27 GP contract for the level of activity delivered by general practice.
28 Apr 2026·Department of Health and Social Care·Pending
AskedWhat estimate he has made of the workload and associated cost to GP practices arising from the expansion of Advice and Refer under the 2026/27 GP contract; and what funding has been allocated to general practice to cover those costs.
28 Apr 2026·Department of Health and Social Care·Pending
AskedWhat assessment he has made of the potential impact of the 2026-27 GP contract on continuity of care; and whether he has evaluated the cost-effectiveness of reduced continuity.
17 Apr 2026·Department of Health and Social Care·Answered
AskedWhether his department plans to review prescription charge exemptions for people who require lifelong medication following a cardiac arrest.
ReplyThere are no current plans to add cardiac arrest to the list of medical conditions that entitle someone to apply for a medical exemption certificate, and no discussions have been held with NHS England on this matter.People who require long-term heart medication may be eligible for exemption from National Health Service prescription charges for another reason. Eligibility depends on the patient’s age, whether they are in qualifying full-time education, whether they are pregnant or have recently given birth, whether they have a qualifying medical condition, and whether they are in receipt of certain benefits or a war pension.Additionally, people on a low income can seek help under the NHS Low Income Scheme, and people who have to pay NHS prescription charges and need many prescription items could save money with a prescription prepayment certificate.
17 Apr 2026·Department of Health and Social Care·Answered
AskedWhat steps he is taking to ensure that people access long‑term heart medication given the level of prescription charges.
ReplyThere are no current plans to add cardiac arrest to the list of medical conditions that entitle someone to apply for a medical exemption certificate, and no discussions have been held with NHS England on this matter.People who require long-term heart medication may be eligible for exemption from National Health Service prescription charges for another reason. Eligibility depends on the patient’s age, whether they are in qualifying full-time education, whether they are pregnant or have recently given birth, whether they have a qualifying medical condition, and whether they are in receipt of certain benefits or a war pension.Additionally, people on a low income can seek help under the NHS Low Income Scheme, and people who have to pay NHS prescription charges and need many prescription items could save money with a prescription prepayment certificate.
17 Apr 2026·Department of Health and Social Care·Answered
AskedWhat recent discussions his Department has had with NHS England on expanding medical exemption criteria to include cardiac arrest survivors dependent on long‑term rhythm‑stabilising medication.
ReplyThere are no current plans to add cardiac arrest to the list of medical conditions that entitle someone to apply for a medical exemption certificate, and no discussions have been held with NHS England on this matter.People who require long-term heart medication may be eligible for exemption from National Health Service prescription charges for another reason. Eligibility depends on the patient’s age, whether they are in qualifying full-time education, whether they are pregnant or have recently given birth, whether they have a qualifying medical condition, and whether they are in receipt of certain benefits or a war pension.Additionally, people on a low income can seek help under the NHS Low Income Scheme, and people who have to pay NHS prescription charges and need many prescription items could save money with a prescription prepayment certificate.
17 Apr 2026·Department of Health and Social Care·Answered
AskedWhether NHS England plans to update its clinical guidance on long‑term support for cardiac arrest survivors, including access to free medication.
ReplyNHS England is focused on improving long‑term, holistic follow‑up and rehabilitation after cardiac arrest. In December 2024, to support local systems to commission high quality cardiac rehabilitation, NHS England published Commissioning standards for cardiac rehabilitation, which is available at the following link:https://www.england.nhs.uk/long-read/commissioning-standards-for-cardiovascular-rehabilitation/Access to prescribed medicines is determined through existing medicines and prescribing policy.
16 Apr 2026·Department of Health and Social Care·Answered
AskedWhat steps are required for vaccines for the prevention of recurrent urinary tract infections to obtain regulatory approval including an indicative timeline for licensing.
ReplyFor any new medicine to be introduced to the United Kingdom market an application to the Medicines and Healthcare products Regulatory Agency (MHRA) is required. The MHRA is ready to support companies that are looking to introduce new medicines to the United Kingdom market, offering regulatory and scientific advice to help companies at any stage of the product development process. The MHRA has established procedures in place to review any applications we receive to evaluate the benefit risk of a product in relation to its quality, safety, and efficacy. The exact timeframe will depend on the type of submission the company makes.